Online citations, reference lists, and bibliographies.
← Back to Search

Effect Of Riluzole On Weight In Short-term And Long-term Survivors Of Amyotrophic Lateral Sclerosis

Kinjal Thakor, S. Naud, D. Howard, R. Tandan, W. Waheed
Published 2021 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Abstract Introduction Riluzole is the first disease-modifying therapy for amyotrophic lateral sclerosis (ALS) approved in 1995 by the Food and Drug Administration in the USA, and is now available worldwide. It delays time to tracheostomy or death and prolongs survival. The precise mechanism of the survival prolonging effect is unknown. Malnutrition and ensuing weight loss are associated with shorter survival in ALS. Given the life-prolonging effects of riluzole and nutritional maintenance, we examined the relationship between riluzole and weight in ALS patients. Materials and Methods: Using data from the National ALS Center of Excellence clinic database at the University of Vermont Medical Center, we stratified 244 patients into cohorts based on riluzole use, and duration of survival from the baseline visit into short-term (≤3 years) and long-term (>3 years) survivors. We examined average monthly weight change in patients during the first year after the baseline visit, and the last year before death. Results and Discussion: In 156 short-term survivors taking riluzole compared to those not taking riluzole, there was a 37% attenuation of weight loss in the first year after baseline, and 46% attenuation of weight loss in the last year before death. Seventy-four n long-term survivors on riluzole showed reduced weight decline in the first year after the baseline visit. We speculate that one mechanism by which riluzole may affect survival is by attenuating weight loss and possibly maintaining nutritional status and body composition, although this warrants prospective study.
This paper references
10.1056/NEJM199403033300901
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
G. Bensimon (1994)
Riluzole Group. A controlled trial of riluzole in amyotrophic lateral sclerosis
G Bensimon (1994)
10.1016/S0140-6736(96)91680-3
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral SclerosisRiluzole Study Group (1996)
Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
L Lacomblez (1996)
10.1001/ARCHNEUR.55.4.526
An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole.
M. Rivière (1998)
10.1080/146608200300079536
El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
B. Brooks (2000)
Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
BR Brooks (2000)
10.1016/S0022-510X(01)00630-X
The epidemiology of motor neuron diseases: a review of recent studies
P. Worms (2001)
Survival in nonriluzole treated amyotrophic lateral sclerosis (ALS) – motor neuron disease (MND) patients with disease onset before and since 1996 is identical: a clinic-based epidemiological study
BR Brooks (2001)
BR Brooks (2001)
10.1002/mds.10229
Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
J. Schiefer (2002)
10.1080/14660820310002601
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
R. Miller (2002)
10.1007/s004150200071
A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis
G. Bensimon (2002)
Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis
G Bensimon (2002)
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
R. Miller (2003)
10.1093/AJE/KWH090
A modified poisson regression approach to prospective studies with binary data.
G. Zou (2004)
10.1212/01.wnl.0000194316.91908.8a
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS
F. Kimura (2006)
10.1111/J.1471-4159.2006.03913.X
The glutamate/GABA‐glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer
L. K. Bak (2006)
10.1111/j.1468-1331.2006.01575.x
Riluzole and amyotrophic lateral sclerosis survival: a population‐based study in southern Italy
S. Zoccolella (2007)
for the SLAP registry. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in Southern Italy
S Zoccolella (2007)
Samarelli V, et al., for the SLAP registry. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in Southern Italy
S Zoccolella (2007)
10.1016/j.jss.2008.03.013
The effects of riluzole on neurological, brain biochemical, and histological changes in early and late term of sepsis in rats.
H. Toklu (2009)
10.3109/17482960802566824
Prognostic factors in ALS: A critical review
A. Chiò (2009)
10.1080/17482960802226148
Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice
Steven J Del Signore (2009)
10.3109/17482968.2010.482592
A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS
A. Jawaid (2010)
10.1016/j.jns.2010.06.028
Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS
N. Limousin (2010)
10.2174/092986710791163939
Riluzole, neuroprotection and amyotrophic lateral sclerosis.
B. Cheah (2010)
10.1136/jnnp.2010.211474
Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients
B. Marin (2010)
10.1097/wco.0b013e328356d328
Amyotrophic lateral sclerosis.
A. Ludolph (2012)
10.2188/jea.JE20120119
Riluzole and Prognostic Factors in Amyotrophic Lateral Sclerosis Long-term and Short-term Survival: A Population-Based Study of 1149 Cases in Taiwan
C. T. Lee (2013)
10.1136/bmj.h1286
Bias in observational study designs: cross sectional studies
P. Sedgwick (2015)
10.3109/21678421.2015.1091478
Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters
K. Boylan (2015)
10.1159/000369813
Epidemiology of Amyotrophic Lateral Sclerosis and Effect of Riluzole on Disease Course
H. Cetin (2015)
10.1080/21678421.2016.1188961
Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS
N. Geevasinga (2016)
10.2147/DNND.S135748
Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
M. Hinchcliffe (2017)
Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis
M Hinchcliffe (2017)
M Hinchcliffe (2017)
10.1016/S1474-4422(18)30054-1
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Ton Fang (2018)
10.1007/978-3-319-40007-5
Handbook of Famine, Starvation, and Nutrient Deprivation
V. Preedy (2018)
10.1007/s00415-018-8778-y
Riluzole and other prognostic factors in ALS: a population-based registry study in Italy
J. Mandrioli (2018)
10.1080/21678421.2017.1413117
Hydration measured by doubly labeled water in ALS and its effects on survival
Connor Scagnelli (2018)
10.1007/978-3-319-40007-5_109-1
Nutritional Consequences of Amyotrophic Lateral Sclerosis
R. Tandan (2019)
10.1136/jnnp-2018-319611
Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort
C. Moglia (2019)
10.1016/j.cmet.2019.11.019
Glutamine Links Obesity to Inflammation in Human White Adipose Tissue.
P. Petrus (2019)
10.3390/nu11030536
Oral Glutamine Supplementation Reduces Obesity, Pro-Inflammatory Markers, and Improves Insulin Sensitivity in DIO Wistar Rats and Reduces Waist Circumference in Overweight and Obese Humans
Kahlile Youssef Abboud (2019)
R Tandan (2019)
Piemonte and Valle d’Aosta Register for ALS (PARALS). Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort
C Moglia (2019)
10.1016/j.neuropharm.2020.107986
Disease-modifying therapies in amyotrophic lateral sclerosis
A. Chiò (2020)



Semantic Scholar Logo Some data provided by SemanticScholar